Antidepressants Market Size

1. The global antidepressants market is projected to grow from $14.93 billion in 2020 to $18.29 billion by 2027, with a compound annual growth rate (CAGR) of 2.9%. North America dominates with 51.41% market share, led by major pharmaceutical companies like Pfizer and Merck. Key market developments include:  COVID-19 Impact: The pandemic caused a surge in depression medication demand, with sales reaching $14.93 billion in 2020 due to increased mental health issues  Market Leaders: Major players include H. Lundbeck A/S, Eli Lilly, AstraZeneca, and Bristol- Myers Squibb  Distribution Channels: Hospital pharmacies lead the market, followed by retail and online pharmacies  Drug Classes: Selective Serotonin Reuptake Inhibitors (SSRIs) hold the largest market share as of 2019 Recent strategic developments in 2024-2025 include:  Eli Lilly's $50 billion U.S. manufacturing investment expansion  AstraZeneca's $1.2 billion acquisition of Gracell Biotechnologies  Bristol-Myers Squibb's $14 billion acquisition of Karuna Therapeutics The market faces challenges including medication side effects and treatment gaps, particularly in emerging countries where approximately 90% of patients with mental disorders remain untreated. Market growth drivers include increasing mental health awareness, strong drug development pipelines, and rising depression diagnosis rates. However, side effects of current therapeutics and treatment gaps in emerging markets remain key challenges. Reports- Fortune Business Insights - Antidepressants Market Size, Share & COVID-19 Impact Analysis https://www.fortunebusinessinsights.com/antidepressants-market-105017